VANCOUVER, Aug. 8, 2017 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today reported financial results for the second quarter ended June 30, 2017 and commented on recent accomplishments and plans.
“Our second quarter was marked by several business development and regulatory accomplishments which pave the way for increased access to our products internationally,” commented William Hunter, MD, CEO and President of Cardiome. “Our commercial launch of BRINAVESS® in Canada continues to expand our geographic footprint, and we look forward to making additional products available to our Canadian sales force as we work alongside the provincial formularies.
